ESMO data arrive October 23 for Innovent stock

Published on 10/15/2026 at 21:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached CNY 8.50 billion. Innovent stock costs EUR 10.01 on October 15, 2026, down 0.40 percent on the Hong Kong exchange.

Pipeline timing and trading

Innovent's ESMO data are scheduled for October 23, 2026.
Second-quarter revenue reached CNY 8.50 billion in 2026.
Innovent stock costs EUR 10.01 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, down 0.40 percent on Hong Kong.
Innovent's valuation was P/E 111.80 at a market capitalization of HKD 153.0 billion.

Innovent, KYG4818G1010, Illustration mit AI erstellt.

ESMO data for Innovent are scheduled for October 23, 2026, when the company is due to present clinical results from its oncology pipeline in Madrid. PR Newswire reported on September 23, 2026, that Innovent's IBI343 trial had secured a late-breaking presentation slot at the European Society for Medical Oncology meeting. Innovent stock costs EUR 10.01 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, down 0.40 percent on the day on Hong Kong.

Revenue reached CNY 8.50 billion

Innovent's second-quarter 2026 revenue came to CNY 8.50 billion, while net income reached CNY 1.24 billion. The figures put the company's commercial base alongside its upcoming clinical readouts, giving investors two separate markers for the October calendar.

Price sits below HKD 112.70

On Hong Kong, Innovent last stood at HKD 87.75 on October 15, 2026 at 4:08 p.m. HKT, with the market closed. The quote was 22.14 percent below the HKD 112.70 52-week high and 26.17 percent above the HKD 69.55 low. Trading volume reached 9,924,840 shares against an average of 11,999,378.

Valuation and October 23 date

The market capitalization stood at HKD 153.0 billion, while the trailing P/E ratio was 111.80 on October 15, 2026. The next scheduled company-linked date is October 23, 2026, when the ESMO program includes the first interim analysis of the phase 3 G-HOPE-001 study, according to the September 23 release carried by PR Newswire.

Comparison with peers

Innovent (HKEX, HKD): minus 0.40 percent, P/E 111.80, market capitalization HKD 153.0 billion
WuXi Biologics (HKEX, HKD): minus 2.21 percent, P/E 34.89, market capitalization HKD 200.2 billion
Sino Biopharmaceutical (HKEX, HKD): plus 2.03 percent, P/E 33.99, market capitalization HKD 93.9 billion

The euro quote after hours

The euro quotation places Innovent's German trading indication at EUR 10.01, while the Hong Kong listing provides the day's exchange-based comparison. The wider range remains important: the HKD 112.70 high is materially above the latest HKD 87.75 quote, whereas the HKD 69.55 low is further below it.

The further course of trading is shown by the continuously updated real-time quote of Innovent stock.